Narrative Update • Jun 29
Have your own idea? Try our Stock Screener
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedJul 09, 2026
DataAggregated Company Financials
Companies27
- 7D-6.3%
- 3M2.3%
- 1Y31.3%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 6.3%, driven by declines in Shanghai Haoyuan Chemexpress and Hangzhou Tigermed Consulting of 8.3% and 4.2%, respectively. Meanwhile, Pharmaron Beijing actually outperformed within the industry, gaining 6.4% in the last week. Over the past 12 months, the industry was up 31%. Looking forward, earnings are forecast to grow by 19% annually.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 09 Jul 2026 | CN¥620.4b | CN¥98.8b | CN¥21.9b | 59.6x | 28.4x | 6.3x |
| Sat, 06 Jun 2026 | CN¥532.6b | CN¥98.8b | CN¥21.9b | 48.3x | 24.4x | 5.4x |
| Mon, 04 May 2026 | CN¥617.3b | CN¥98.4b | CN¥21.7b | 58.6x | 28.5x | 6.3x |
| Wed, 01 Apr 2026 | CN¥570.2b | CN¥95.0b | CN¥20.6b | 57x | 27.7x | 6x |
| Fri, 27 Feb 2026 | CN¥590.5b | CN¥94.4b | CN¥18.6b | 69.3x | 31.8x | 6.3x |
| Sun, 25 Jan 2026 | CN¥613.9b | CN¥94.3b | CN¥18.5b | 65.4x | 33.1x | 6.5x |
| Tue, 23 Dec 2025 | CN¥550.0b | CN¥94.3b | CN¥18.5b | 61x | 29.7x | 5.8x |
| Thu, 20 Nov 2025 | CN¥556.7b | CN¥94.3b | CN¥18.5b | 66.3x | 30x | 5.9x |
| Sat, 18 Oct 2025 | CN¥570.0b | CN¥92.1b | CN¥17.4b | 63.1x | 32.7x | 6.2x |
| Mon, 15 Sep 2025 | CN¥625.3b | CN¥92.1b | CN¥17.4b | 72.1x | 35.9x | 6.8x |
| Wed, 13 Aug 2025 | CN¥569.0b | CN¥91.6b | CN¥17.9b | 59.3x | 31.8x | 6.2x |
| Fri, 11 Jul 2025 | CN¥464.3b | CN¥89.8b | CN¥15.4b | 51.8x | 30.2x | 5.2x |
| Sun, 08 Jun 2025 | CN¥421.7b | CN¥89.8b | CN¥15.4b | 48.1x | 27.4x | 4.7x |
| Tue, 06 May 2025 | CN¥390.9b | CN¥89.5b | CN¥15.1b | 40x | 25.9x | 4.4x |
| Thu, 03 Apr 2025 | CN¥437.0b | CN¥88.5b | CN¥14.0b | 45.8x | 31.2x | 4.9x |
| Sat, 01 Mar 2025 | CN¥419.2b | CN¥88.2b | CN¥11.2b | 42.2x | 37.4x | 4.8x |
| Mon, 27 Jan 2025 | CN¥361.5b | CN¥88.1b | CN¥11.2b | 38.1x | 32.1x | 4.1x |
| Wed, 25 Dec 2024 | CN¥379.8b | CN¥87.8b | CN¥11.2b | 39.1x | 34x | 4.3x |
| Fri, 22 Nov 2024 | CN¥378.2b | CN¥87.8b | CN¥11.2b | 40.2x | 33.8x | 4.3x |
| Sun, 20 Oct 2024 | CN¥360.2b | CN¥88.2b | CN¥12.4b | 32.6x | 29.1x | 4.1x |
| Tue, 17 Sep 2024 | CN¥279.8b | CN¥88.2b | CN¥12.4b | 27.5x | 22.6x | 3.2x |
| Thu, 15 Aug 2024 | CN¥282.3b | CN¥87.6b | CN¥12.6b | 26.5x | 22.5x | 3.2x |
| Sat, 13 Jul 2024 | CN¥279.1b | CN¥88.3b | CN¥13.4b | 24.6x | 20.8x | 3.2x |
| Mon, 10 Jun 2024 | CN¥303.0b | CN¥88.3b | CN¥13.4b | 26.8x | 22.6x | 3.4x |
| Wed, 08 May 2024 | CN¥339.5b | CN¥88.3b | CN¥13.3b | 31.6x | 25.5x | 3.8x |
| Fri, 05 Apr 2024 | CN¥337.9b | CN¥90.3b | CN¥15.0b | 33.6x | 22.5x | 3.7x |
| Sun, 03 Mar 2024 | CN¥364.9b | CN¥90.5b | CN¥15.5b | 31.8x | 23.5x | 4x |
| Tue, 30 Jan 2024 | CN¥377.9b | CN¥91.1b | CN¥16.1b | 33.9x | 23.5x | 4.1x |
| Thu, 28 Dec 2023 | CN¥460.1b | CN¥91.1b | CN¥16.1b | 36.8x | 28.6x | 5.1x |
| Sat, 25 Nov 2023 | CN¥535.8b | CN¥91.1b | CN¥16.1b | 39.8x | 33.3x | 5.9x |
| Mon, 23 Oct 2023 | CN¥511.8b | CN¥92.2b | CN¥18.4b | 33.4x | 27.8x | 5.5x |
| Wed, 20 Sep 2023 | CN¥492.1b | CN¥92.0b | CN¥18.3b | 32.7x | 26.8x | 5.4x |
| Fri, 18 Aug 2023 | CN¥496.8b | CN¥91.6b | CN¥18.6b | 34.5x | 26.8x | 5.4x |
| Sun, 16 Jul 2023 | CN¥470.9b | CN¥91.3b | CN¥18.5b | 34.9x | 25.5x | 5.2x |
Price to Earnings Ratio
25.5x
Current Industry PE
- Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 28.7x.
- The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 5.8% per year over the last three years.
- Revenues for these companies have grown 2.7% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | -6.07% | |
| Healthcare | -2.35% | |
| Life Sciences | -6.35% | |
| Clinical Research and Equipment | -6.35% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 300759 Pharmaron Beijing | CN¥30.98 | 6.4% +CN¥3.4b | 23.4% | PE33.5x | |
| 688114 MGI Tech | CN¥55.88 | 7.6% +CN¥1.6b | -10.9% | PS8x | |
| 688222 HitGen | CN¥33.45 | 7.7% +CN¥961.6m | 98.3% | PE109.2x | |
| 301520 Anhui Wanbang Pharmaceutical TechnologyLtd | CN¥41.60 | 32.5% +CN¥946.2m | 29.7% | PE158.7x | |
| 688068 Beijing Hotgen Biotech | CN¥119.84 | 8.8% +CN¥850.7m | -36.9% | PS24.7x |